These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 21395631)

  • 1. Enteric-coated cysteamine for the treatment of paediatric non-alcoholic fatty liver disease.
    Dohil R; Schmeltzer S; Cabrera BL; Wang T; Durelle J; Duke KB; Schwimmer JB; Lavine JE
    Aliment Pharmacol Ther; 2011 May; 33(9):1036-44. PubMed ID: 21395631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endoscopic duodenal-jejunal bypass liner rapidly improves plasma parameters of nonalcoholic fatty liver disease.
    de Jonge C; Rensen SS; Koek GH; Joosten MF; Buurman WA; Bouvy ND; Greve JW
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1517-20. PubMed ID: 23920034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of cysteamine bitartrate on adiponectin multimerization in non-alcoholic fatty liver disease and healthy subjects.
    Dohil R; Meyer L; Schmeltzer S; Cabrera BL; Lavine JE; Phillips SA
    J Pediatr; 2012 Oct; 161(4):639-45.e1. PubMed ID: 22633783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In Children With Nonalcoholic Fatty Liver Disease, Cysteamine Bitartrate Delayed Release Improves Liver Enzymes but Does Not Reduce Disease Activity Scores.
    Schwimmer JB; Lavine JE; Wilson LA; Neuschwander-Tetri BA; Xanthakos SA; Kohli R; Barlow SE; Vos MB; Karpen SJ; Molleston JP; Whitington PF; Rosenthal P; Jain AK; Murray KF; Brunt EM; Kleiner DE; Van Natta ML; Clark JM; Tonascia J; Doo E;
    Gastroenterology; 2016 Dec; 151(6):1141-1154.e9. PubMed ID: 27569726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of silymarin plus vitamin E in patients with non-alcoholic fatty liver disease. A randomized clinical pilot study.
    Aller R; Izaola O; Gómez S; Tafur C; González G; Berroa E; Mora N; González JM; de Luis DA
    Eur Rev Med Pharmacol Sci; 2015 Aug; 19(16):3118-24. PubMed ID: 26367736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term treatment of cystinosis in children with twice-daily cysteamine.
    Dohil R; Gangoiti JA; Cabrera BL; Fidler M; Schneider JA; Barshop BA
    J Pediatr; 2010 May; 156(5):823-7. PubMed ID: 20138296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of vitamin E on aminotransferase levels and insulin resistance in children with non-alcoholic fatty liver disease.
    Nobili V; Manco M; Devito R; Ciampalini P; Piemonte F; Marcellini M
    Aliment Pharmacol Ther; 2006 Dec; 24(11-12):1553-61. PubMed ID: 17206944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease.
    McPherson S; Stewart SF; Henderson E; Burt AD; Day CP
    Gut; 2010 Sep; 59(9):1265-9. PubMed ID: 20801772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of enteric-coated cysteamine bitartrate in healthy adults: a pilot study.
    Gangoiti JA; Fidler M; Cabrera BL; Schneider JA; Barshop BA; Dohil R
    Br J Clin Pharmacol; 2010 Sep; 70(3):376-82. PubMed ID: 20716238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 2 clinical trial of metformin as a treatment for non-diabetic paediatric non-alcoholic steatohepatitis.
    Schwimmer JB; Middleton MS; Deutsch R; Lavine JE
    Aliment Pharmacol Ther; 2005 Apr; 21(7):871-9. PubMed ID: 15801922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study.
    Nobili V; Manco M; Ciampalini P; Alisi A; Devito R; Bugianesi E; Marcellini M; Marchesini G
    Clin Ther; 2008 Jun; 30(6):1168-76. PubMed ID: 18640473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lifestyle intervention for non-alcoholic fatty liver disease: prospective cohort study of its efficacy and factors related to improvement.
    Koot BG; van der Baan-Slootweg OH; Tamminga-Smeulders CL; Rijcken TH; Korevaar JC; van Aalderen WM; Jansen PL; Benninga MA
    Arch Dis Child; 2011 Jul; 96(7):669-74. PubMed ID: 21518734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease.
    Maximos M; Bril F; Portillo Sanchez P; Lomonaco R; Orsak B; Biernacki D; Suman A; Weber M; Cusi K
    Hepatology; 2015 Jan; 61(1):153-60. PubMed ID: 25145475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-alcoholic fatty liver disease in obese children evaluated by magnetic resonance imaging.
    Radetti G; Kleon W; Stuefer J; Pittschieler K
    Acta Paediatr; 2006 Jul; 95(7):833-7. PubMed ID: 16801180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acetyl-L-carnitine and lipoic acid improve mitochondrial abnormalities and serum levels of liver enzymes in a mouse model of nonalcoholic fatty liver disease.
    Kathirvel E; Morgan K; French SW; Morgan TR
    Nutr Res; 2013 Nov; 33(11):932-41. PubMed ID: 24176233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Glucagon-Like Peptide-1 Analogue Liraglutide Inhibits Oxidative Stress and Inflammatory Response in the Liver of Rats with Diet-Induced Non-alcoholic Fatty Liver Disease.
    Gao H; Zeng Z; Zhang H; Zhou X; Guan L; Deng W; Xu L
    Biol Pharm Bull; 2015; 38(5):694-702. PubMed ID: 25947915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients.
    Gómez-Domínguez E; Gisbert JP; Moreno-Monteagudo JA; García-Buey L; Moreno-Otero R
    Aliment Pharmacol Ther; 2006 Jun; 23(11):1643-7. PubMed ID: 16696815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intestinal permeability after Mediterranean diet and low-fat diet in non-alcoholic fatty liver disease.
    Biolato M; Manca F; Marrone G; Cefalo C; Racco S; Miggiano GA; Valenza V; Gasbarrini A; Miele L; Grieco A
    World J Gastroenterol; 2019 Jan; 25(4):509-520. PubMed ID: 30700946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omega-3 Fatty acids therapy in children with nonalcoholic Fatty liver disease: a randomized controlled trial.
    Janczyk W; Lebensztejn D; Wierzbicka-Rucińska A; Mazur A; Neuhoff-Murawska J; Matusik P; Socha P
    J Pediatr; 2015 Jun; 166(6):1358-63.e1-3. PubMed ID: 25771388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lifestyle intervention in obese children with non-alcoholic fatty liver disease: 2-year follow-up study.
    Reinehr T; Schmidt C; Toschke AM; Andler W
    Arch Dis Child; 2009 Jun; 94(6):437-42. PubMed ID: 19224892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.